TABLE 2.
In Vivo Cohort: Main Clinical and Demographic Characteristics
| Original cohort | Validation cohort | |
|---|---|---|
| Participants, n | 25 | 66 |
| Sex, n (%) | ||
| Female | 19 (76%) | 50 (76%) |
| Male | 6 (24%) | 16 (24%) |
| Age (years), mean (SD) | 39 (9.5) | 48 (12.5) |
| Clinical phenotype, n (%) | ||
| Clinically isolated syndrome | 2 (8%) | 0 (0%) |
| Relapsing–remitting | 22 (88%) | 47 (71%) |
| Secondary progressive | 1 (4%) | 15 (23%) |
| Primary progressive | 0 (0%) | 4 (6%) |
| Disease duration (years), median (IQR) | 4.5 (8) | 12 (14.7) |
| Disease‐modifying treatment | ||
| Untreated | 14 (56%) | 21 (32%) |
| Glatiramer acetate | 5 (20%) | 5 (8%) |
| Interferon beta | 4 (16%) | 8 (12%) |
| Dimethyl fumarate | 1 (4%) | 8 (12%) |
| Daclizumab | 1 (4%) | 1(1%) |
| Anti‐CD20 | 0 (0%) | 12 (18%) |
| Fingolimod | 0 (0%) | 6 (9%) |
| Teriflunomide | 0 (0%) | 3 (5%) |
| Natalizumab | 0 (0%) | 2 (3%) |
| EDSS score, median (IQR) | 1.5 (1) | 2 (4) |
| MSSS score, median (IQR) | 2 (2.8) | 1.8 (3.8) |
| PASAT score, median (IQR) | 53 (16) | 50 (17) |
| SDMT score, median (IQR) | 54 (16) | 49 (19) |
| # of CEL lesions per scan, median (IQR) | 2 (3) | NA |
| # of scans with CEL per case, median (IQR) | 2 (3) | NA |
| Total lesion volume (ml), median (IQR) | 11.4 (12.5) | 17 (32.9) |
| Follow‐up time (years), median (IQR) | 4.2 (9.8) | NA |
All values except for contrast‐enhancing lesions are computed at the time of 7‐tesla scanning.
CEL = contrast enhancing lesion; EDSS = Expanded Disability Status Scale; IQR = Interquartile range; MSSS = Multiple Sclerosis Severity Score; PASAT = Paced Auditory Serial Addition Test; SDMT = Symbol Digit Modalities Test.